Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Peer Review reports

Original Submission
24 Jul 2023	Submitted	Original manuscript
11 Sep 2023	Reviewed	Reviewer Report - Shebli Atrash
22 Sep 2023	Reviewed	Reviewer Report
2 Oct 2023	Author responded	Author comments - Joseph Kauer
Resubmission - Version 2
2 Oct 2023	Submitted	Manuscript version 2
Publishing
10 Oct 2023	Editorially accepted
21 Nov 2023	Article published	10.1186/s12885-023-11507-9

Back to article page